MedTrace Logo

Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors

NCT00382161 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-02-13

No results posted yet for this study

Summary

The purpose of the study is to determine the effect of fluvastatin on penile arterial blood flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.

Conditions

  • Impotence

Interventions

DRUG

Fluvastatin-sodium

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital, Saarland

    lead OTHER

Principal Investigators

  • Magnus Baumhäkel, MD · University Hospital of the Saarland

  • Michael Böhm, MD · University Hospital of the Saarland

  • Martin Gerber, MD · University Hospital of the Saarland

  • Michael Stöckle, MD · University Hospital of the Saarland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2007-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382161 on ClinicalTrials.gov